EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility

Daniel Golparian, Susanne Jacobsson, Leonor Sánchez-Busó, Maria Luiza Bazzo, Pham Thi Lan, Patricia Galarza, Makoto Ohnishi, Magnus Unemo iD

Journal of Antimicrobial Chemotherapy · 2023-01-05 · 78 (1) · 150-154

DOI: 10.1093/jac/dkac366 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Antimicrobial Chemotherapy, published online on 2022-10-29. Written by Daniel Golparian and 7 co-authors. Institution: Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitt…. Major MEDLINE topics: Gonorrhea, Anti-Infective Agents. Cited 37 times so far (Crossref); 20 references. Funded by: Örebro County Council Research Committee, Conselleria de Sanitat Universal i Salut Pública, Generalitat Valenciana.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a global threat and novel treatment alternatives are imperative. Herein, susceptibility to the novel antimicrobial zoliflodacin, currently in a global Phase 3 randomized controlled clinical trial for gonorrhoea treatment, was investigated by screening for zoliflodacin GyrB target mutations in publicly available gonococcal genomes and, where feasible, determination of the associated zoliflodacin MIC.

Methods

The European Nucleotide Archive was queried using the search term ‘Taxon: 485’. DNA sequences from 27 151 gonococcal isolates were analysed and gyrB, gyrA, parC and parE alleles characterized.

Results

GyrB amino acid alterations were rare (97.0% of isolates had a wild-type GyrB sequence). GyrB V470L (2.7% of isolates) was the most prevalent alteration, followed by S467N (0.12%), N. meningitidis GyrB (0.092%), V470I (0.059%), Q468R/P (0.015%), A466T (0.0074%), L425I + L465I (0.0037%), L465I (0.0037%), G482S (0.0037%) and D429V (0.0037%). Only one isolate (0.0037%) carried a substitution in a resistance-associated GyrB codon (D429V), resulting in a zoliflodacin MIC of 8 mg/L. None of the other detected gyrB, gyrA, parC or parE mutations caused a zoliflodacin MIC outside the wild-type MIC distribution.

Conclusions

The zoliflodacin target GyrB was highly conserved among 27 151 global gonococcal isolates cultured in 1928–2021. The single zoliflodacin-resistant clinical isolate (0.0037%) was cultured from a male patient in Japan in 2000. Evidently, this strain has not clonally expanded nor has the gyrB zoliflodacin-resistance mutation disseminated through horizontal gene transfer to other strains. Phenotypic and genomic surveillance, including gyrB mutations, of zoliflodacin susceptibility are imperative.

Subjects

MeSH terms (MEDLINE)

GonorrheaAnti-Infective AgentsMaleHumansAnti-Bacterial AgentsDNA GyraseDNA Topoisomerase IVNeisseria gonorrhoeaeMutationMicrobial Sensitivity TestsDrug Resistance, BacterialBarbituratesIsoxazolesMorpholinesSpiro CompoundsOxazolidinones

Substances

Anti-Bacterial AgentsDNA GyraseDNA Topoisomerase IVAnti-Infective AgentszoliflodacinBarbituratesIsoxazolesMorpholinesSpiro CompoundsOxazolidinones

Authors and institutions

  • Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, Örebro University, Örebro, Sweden.
  • Genomics and Health Area, Foundation for the Promotion of Health and Biomedical Research in the Valencian Community (FISABIO-Public Health), Valencia, Spain and Consortium for Biomedical Research in Epidemiology and Pub…
  • Molecular Biology, Microbiology and Serology Laboratory, Federal University of Santa Catarina, Florianópolis, Brazil.
  • Hanoi Medical University, National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
  • National Reference Laboratory for STDs, National Institute of Infectious Diseases-ANLIS 'Dr Carlos G. Malbrán', Buenos Aires, Argentina.
  • Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.

ORCID profiles: Magnus Unemo

Funding

  • Örebro County Council Research Committee
  • Conselleria de Sanitat Universal i Salut Pública
  • Generalitat Valenciana

Cite

APA

Golparian, D., Jacobsson, S., Sánchez-Busó, L., Bazzo, M. L., Lan, P. T., Galarza, P., Ohnishi, M., & Unemo, M. (2023). GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility. Journal of Antimicrobial Chemotherapy, 78(1), 150-154. https://doi.org/10.1093/jac/dkac366

Vancouver

Golparian D, Jacobsson S, Sánchez-Busó L, Bazzo ML, Lan PT, Galarza P, et al. GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility. Journal of Antimicrobial Chemotherapy. 2023;78(1):150-154. doi:10.1093/jac/dkac366

BibTeX
@article{Golparian2023,
  author = {Golparian, Daniel and Jacobsson, Susanne and Sánchez-Busó, Leonor and Bazzo, Maria Luiza and Lan, Pham Thi and Galarza, Patricia and Ohnishi, Makoto and Unemo, Magnus},
  title = {GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {1},
  pages = {150--154},
  doi = {10.1093/jac/dkac366}
}
Start for free →